Lonza Group LONN.SW · CHF

Its shares trade on SIX under the ticker LONN.SW. It has been listed since 3 April 2002. In the fiscal year to 31 December 2025, it reported revenue of CHF 6.53bn and net income of CHF 949.0m. At that date it held total assets of CHF 18.97bn and shareholders' equity of CHF 9.13bn.

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. The company is headquartered in Basel, Basel-Stadt. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Jean Marc HuetIndependent Non-Executive Chairman of the BoardCHF 547,742
• Dr. Wolfgang WienandChief Executive Officer, Member of the Executive CommitteeCHF 6.4m
• Mr. Juergen SteinemannIndependent Non-Executive Vice Chairman of the BoardCHF 255,773
• Mr. Philippe DeeckeChief Financial Officer, Member of the Executive Committee
• Ms. Nicoleta BaumgartnerChief Human Resources Officer, Member of the Executive Committee
• Mr. Gordon BatesHead of Integrated Biologics, Member of the Executive Committee
• Mr. Jason BerndtHead of Group Operations and Member of the Executive Committee
• Mr. Andreas BohrerChief Legal & Corporate Affairs Officer and Member of the Executive Committee
• Mr. Jean-Christophe HyvertHead of Capsules & Health Ingredients, Member of the Executive Committee
• Ms. Maria NunezChief Quality Officer, Member of the Executive Committee
• Mr. Daniel PalmacciHead of Specialized Modalities, Member of the Executive Committee
• Mr. Christian SeufertHead of Advanced Synthesis, Member of the Executive Committee

Overall

96

Environment

99

Social

99

Governance

91

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.